Abstract #0824

MR-HIFU mild hyperthermia for sensitization of radiation and chemotherapy for recurrent rectal cancer: First phase I clinical trial results.

William Chu¹, Robert Staruch², Samuel Pichardo^3,4, Yuexi Huang⁵, Charles Mougenot⁶, Matti Tillander⁷, Max O. Köhler⁷, Mika Ylihautala⁷, Merrylee McGuffin¹, Gregory Czarnota¹, and Kullervo Hynynen⁵

¹Radiation Oncology, Sunnybrook Health Science Centre, Toronto, ON, Canada, ²Philips Research, Cambridge, MA, United States, ³Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada, ⁴Electrical Engineering, Lakehead University, Thunder Bay, ON, Canada, ⁵Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, ⁶Philips Healthcare, Toronto, ON, Canada, ⁷Philips Healthcare, Vantaa, Finland

We present the first results of a Phase I trial that includes delivery of mild hyperthermia using magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) combined with radiation and chemotherapy in the treatment of locally recurrentrectal cancer. MR-HIFU mild hyperthermia was delivered in three sessions (day 1, 8 and 15) during a 17-day treatment protocol (total dose 30.6 Gy combined with fluropyrimidine-based chemotherapy). MR-HIFU mild hyperthermia was successfully delivered and the procedure was well tolerated by the patient. No adverse effects have been reported 3 months after the treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here